| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2007-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2009-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-WO2007145227-A1 |
| titleOfInvention |
Hematopoietic stem cell increase promoter |
| abstract |
In addition to induction of human megakaryocyte-specific differentiation (increase in platelet progenitor cells) by administration of a low molecular weight agonist antibody (VB22B sc (Fv) 2) to the TPO receptor, the present inventors have obtained blood derived from human umbilical cord blood. We found engraftment of stem cells (CD34 positive cells) and a significant increase in multi-lineage blood progenitor cells. A TPO or TPO receptor agonist is a hematopoietic CD34-positive cell growth promoter or bone marrow that can be expected to have an effect simply by administration after hematopoietic stem cell transplantation (particularly umbilical cord blood transplantation) (without the combined use of G-CSF and erythropoietin) It can be used as an engraftment promoter. Moreover, it can be used as a multi-lineage hematopoietic progenitor cell proliferation and / or differentiation promoter and a multi-lineage hematopoietic recovery promoter. |
| priorityDate |
2006-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |